Market Research Logo

Sarcopenia - Pipeline Review, H2 2015

Sarcopenia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Sarcopenia - Pipeline Review, H2 2015’, provides an overview of the Sarcopenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sarcopenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Sarcopenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Sarcopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Sarcopenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Sarcopenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Sarcopenia Overview
Therapeutics Development
Pipeline Products for Sarcopenia - Overview
Pipeline Products for Sarcopenia - Comparative Analysis
Sarcopenia - Therapeutics under Development by Companies
Sarcopenia - Therapeutics under Investigation by Universities/Institutes
Sarcopenia - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Sarcopenia - Products under Development by Companies
Sarcopenia - Products under Investigation by Universities/Institutes
Sarcopenia - Companies Involved in Therapeutics Development
GlaxoSmithKline Plc
Myos Corporation
Neurotune AG
Novartis AG
PolyNovo Limited
PsiOxus Therapeutics Limited
Regeneron Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Sarcopenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AOD-9604 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARM-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIO-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Espindolol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEP-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proteins for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sarcopenia - Recent Pipeline Updates
Sarcopenia - Dormant Projects
Sarcopenia - Discontinued Products
Sarcopenia - Product Development Milestones
Featured News & Press Releases
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models
Dec 14, 2011: Calzada Announces New Applications For AOD9604
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sarcopenia, H2 2015
Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2015
Sarcopenia - Pipeline by Myos Corporation, H2 2015
Sarcopenia - Pipeline by Neurotune AG, H2 2015
Sarcopenia - Pipeline by Novartis AG, H2 2015
Sarcopenia - Pipeline by PolyNovo Limited, H2 2015
Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Sarcopenia Therapeutics - Recent Pipeline Updates, H2 2015
Sarcopenia - Dormant Projects, H2 2015
Sarcopenia - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Sarcopenia, H2 2015
Number of Products under Development for Sarcopenia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report